GSK•benzinga•
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
Summary
GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 14, 2024 by benzinga